CDK12 induced anti-HER2 therapy inhibitor, while CDK12 inhibition is an effective strategy to inhibit tumor growth.27 In patients receiving HER2 tyrosine inhibitors, CDK12 inhibition suppressed PI3K/AKT signal and showed prominently benefit outcome.28 However, another research using biomarker analysis found that CDK12 amplification was associated with better response in patients receiving KN026, a biospecific HER2 antibody.29 Interestingly, in our study, CDK12 amplification appeared to be associated with similar PFS in our research. The gene discussed is AKT1; the disease is neoplasm.